Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue EMBO Molecular Medicine Année : 2019

Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance

Résumé

Due to compromised homologous recombination (HR) repair, BRCA1- and BRCA2-mutated tumours accumulate DNA damage and genomic rearrangements conducive of tumour progression. To identify drugs that target specifically BRCA2-deficient cells, we screened a chemical library containing compounds in clinical use. The top hit was chlorambucil, a bifunctional alkylating agent used for the treatment of chronic lymphocytic leukaemia (CLL). We establish that chlorambucil is specifically toxic to BRCA1/2-deficient cells, including olaparib-resistant and cisplatin-resistant ones, suggesting the potential clinical use of chlorambucil against disease which has become resistant to these drugs. Additionally, chlorambucil eradicates BRCA2-deficient xenografts and inhibits growth of olaparib-resistant patient-derived tumour xenografts (PDTXs). We demonstrate that chlorambucil inflicts replication-associated DNA double-strand breaks (DSBs), similarly to cisplatin, and we identify ATR, FANCD2 and the SNM1A nuclease as determinants of sensitivity to both drugs. Importantly, chlorambucil is substantially less toxic to normal cells and tissues in vitro and in vivo relative to cisplatin. Because chlorambucil and cisplatin are equally effective inhibitors of BRCA2-compromised tumours, our results indicate that chlorambucil has a higher therapeutic index than cisplatin in targeting BRCA-deficient tumours.
Fichier principal
Vignette du fichier
islandora_152075.pdf (1.04 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04537970 , version 1 (08-04-2024)

Identifiants

Citer

Eliana M.C. Tacconi, Sophie Badie, Giuliana de Gregoriis, Timo Reislander, Xianning Lai, et al.. Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. EMBO Molecular Medicine, 2019, 11 (7), ⟨10.15252/emmm.201809982⟩. ⟨hal-04537970⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More